JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Home・Elenco Azioni・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Chiusa

1.2 -1.64

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.19

Massimo

1.22

Metriche Chiave
By Trading Economics
Entrata	2.7M -24M
EPS	-0.354
Dipendenti	49
EBITDA	-5.3M -28M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+120.66% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-6.2M 75M
Apertura precedente	2.84
Chiusura precedente	1.2

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

1.43 / 1.6 Supporto e resistenza

Pliant Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 apr 2026, 23:33 UTC

Azioni calde

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 apr 2026, 23:24 UTC

Utili

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 apr 2026, 23:15 UTC

Principali Notizie su Eventi

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 apr 2026, 22:46 UTC

Utili

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 apr 2026, 22:37 UTC

Utili

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 apr 2026, 22:15 UTC

Utili

Principali Notizie su Eventi

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 apr 2026, 23:33 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 apr 2026, 23:31 UTC

Utili

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 apr 2026, 23:31 UTC

Utili

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 apr 2026, 23:30 UTC

Utili

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 apr 2026, 23:30 UTC

Utili

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 apr 2026, 23:19 UTC

Discorsi di Mercato

Utili

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 apr 2026, 23:09 UTC

Utili

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 apr 2026, 23:03 UTC

Discorsi di Mercato

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 apr 2026, 23:01 UTC

Principali Notizie su Eventi

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 apr 2026, 22:51 UTC

Utili

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 apr 2026, 22:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 apr 2026, 22:48 UTC

Discorsi di Mercato

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 apr 2026, 22:40 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 apr 2026, 22:32 UTC

Utili

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 apr 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 apr 2026, 22:22 UTC

Utili

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 apr 2026, 22:17 UTC

Discorsi di Mercato

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 apr 2026, 22:14 UTC

Utili

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 apr 2026, 22:14 UTC

Utili

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 apr 2026, 22:07 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Confronto tra pari

Modifica del prezzo

Pliant Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

120.66% in crescita

Previsioni per 12 mesi

Media 2.67 USD 120.66%

Alto 3 USD

Basso 2 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pliant Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Pliant Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.43 / 1.6Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.